Balyasny Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Balyasny Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$441K	Sell	3,598 -97,701	-96%	-$10.2M	﹤0.01%	2577
2026 Q1	$10.7M	Buy	+101,299	New	+$8.97M	0.01%	1006
2024 Q1	–	Sell	-50,503	Closed	-$1.16M	–	3018
2023 Q4	$1.16M	Buy	+50,503	New	+$884K	﹤0.01%	1624
2018 Q3	–	Sell	-39,480	Closed	-$265K	–	1969
2018 Q2	$265K	Buy	39,480 +27,616	+233%	+$212K	﹤0.01%	1554
2018 Q1	$102K	Buy	+11,864	New	+$223K	﹤0.01%	1829

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Balyasny Asset Management's PTGX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 96% in Q2 2026, selling an estimated $10.2M and leaving 3,598 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Balyasny Asset Management first reported a position in PTGX in Q1 2018 and has held it in 5 quarters since. The position peaked at $10.7M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Balyasny Asset Management held 3,598 shares of Protagonist Therapeutics worth $441K as of Q2 2026.
Balyasny Asset Management sold 97,701 Protagonist Therapeutics shares in Q2 2026, an estimated $10.2M.
Protagonist Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2577 holding.
Balyasny Asset Management first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 5 quarters since.
Balyasny Asset Management's Protagonist Therapeutics position peaked at $10.7M in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.